Private equity is increasingly targeting naval‑centric projects, driven by the need to clear a large manufacturing backlog and modernize the U.S. fleet. Dealmakers see a surge in demand for AI and advanced technology, along with a reliable, deep‑pocketed customer in the Navy.

Sheridan Capital Partners has acquired Carolina Components Group, a custom‑engineered bioprocessing assembly provider that serves over 250 biopharmaceutical and contract manufacturing businesses. The deal was led by partner and co‑founder Sean Dempsey.

In the medical device space, KKR plans to take Integer Holdings Corporation private in an all‑cash transaction valued at $5.7bn. The acquisition will focus on expanding Integer’s global manufacturing footprint and talent pool.

CapVest’s portfolio company Curium announced its intention to acquire Lantheus Holdings for approximately $8bn, merging it with a wholly‑owned subsidiary of Curium US to enhance radiopharmaceutical production.

These moves illustrate the broad appeal of defense, biotech, and medical device sectors for private‑equity investors seeking durable, high‑growth opportunities.